KR20200019217A - Pai-1 과다발현과 관련된 병태의 플라스미노겐 치료 - Google Patents

Pai-1 과다발현과 관련된 병태의 플라스미노겐 치료 Download PDF

Info

Publication number
KR20200019217A
KR20200019217A KR1020207001617A KR20207001617A KR20200019217A KR 20200019217 A KR20200019217 A KR 20200019217A KR 1020207001617 A KR1020207001617 A KR 1020207001617A KR 20207001617 A KR20207001617 A KR 20207001617A KR 20200019217 A KR20200019217 A KR 20200019217A
Authority
KR
South Korea
Prior art keywords
plasminogen
pai
disease
subject
overexpression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207001617A
Other languages
English (en)
Korean (ko)
Inventor
라인 가뇽
브리지트 그뤽스
피에르 로랭
Original Assignee
프로메틱 바이오 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메틱 바이오 테라퓨틱스 인코포레이티드 filed Critical 프로메틱 바이오 테라퓨틱스 인코포레이티드
Publication of KR20200019217A publication Critical patent/KR20200019217A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207001617A 2017-06-23 2018-06-22 Pai-1 과다발현과 관련된 병태의 플라스미노겐 치료 Ceased KR20200019217A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
US62/523,901 2017-06-23
PCT/IB2018/000655 WO2018234861A1 (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression

Publications (1)

Publication Number Publication Date
KR20200019217A true KR20200019217A (ko) 2020-02-21

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207001617A Ceased KR20200019217A (ko) 2017-06-23 2018-06-22 Pai-1 과다발현과 관련된 병태의 플라스미노겐 치료

Country Status (21)

Country Link
US (1) US11826404B2 (https=)
EP (1) EP3641888B1 (https=)
JP (1) JP2020524689A (https=)
KR (1) KR20200019217A (https=)
CN (1) CN110831668B (https=)
AU (1) AU2018287316B2 (https=)
BR (1) BR112019027229A2 (https=)
CA (1) CA3068153A1 (https=)
CL (1) CL2019003789A1 (https=)
DK (1) DK3641888T3 (https=)
ES (1) ES2965937T3 (https=)
FI (1) FI3641888T3 (https=)
IL (1) IL271470B2 (https=)
MX (1) MX2019015741A (https=)
MY (1) MY203136A (https=)
NZ (1) NZ760921A (https=)
RU (1) RU2020100080A (https=)
SG (1) SG11201912813SA (https=)
TW (1) TWI868051B (https=)
WO (1) WO2018234861A1 (https=)
ZA (1) ZA202000280B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107686A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗动脉粥样硬化及其并发症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
EP4094775A4 (en) * 2020-02-06 2023-04-19 Talengen International Limited METHODS AND MEDICATIONS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS
US20230173039A1 (en) * 2020-03-24 2023-06-08 Talengen International Limited Method and drug for treating alzheimer disease
EP4122489A4 (en) * 2020-03-24 2023-04-12 Talengen International Limited METHODS AND MEDICATIONS FOR PROMOTING THE BREAKDOWN OF MISFOLDED PROTEIN AND AGGREGATE THEREOF
CN115697386A (zh) * 2020-03-24 2023-02-03 泰伦基国际有限公司 一种治疗帕金森病的方法和药物
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法
WO2026006092A1 (en) * 2024-06-24 2026-01-02 The Cleveland Clinic Foundation Enzyme encapsulated nanoparticles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6677473B1 (en) * 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
US8318661B2 (en) * 2006-08-28 2012-11-27 Omnio Healer Ab Candidates against infection
ES2453496T3 (es) 2006-08-28 2014-04-08 Omnio Healer Ab Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral
HK1221725A1 (zh) * 2013-08-13 2017-06-09 Sanofi 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TW201722464A (zh) 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
JP7242057B2 (ja) 2016-12-15 2023-03-20 タレンゲン インターナショナル リミテッド 薬物性腎損傷を予防及び治療するための方法
JP7213552B2 (ja) * 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
JP7168990B2 (ja) * 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物

Also Published As

Publication number Publication date
JP2020524689A (ja) 2020-08-20
CL2019003789A1 (es) 2020-07-10
SG11201912813SA (en) 2020-01-30
NZ760921A (en) 2026-01-30
EP3641888B1 (en) 2023-10-11
EP3641888A4 (en) 2021-03-10
RU2020100080A3 (https=) 2021-11-02
IL271470B2 (en) 2025-07-01
DK3641888T3 (da) 2024-01-02
ZA202000280B (en) 2021-08-25
MX2019015741A (es) 2020-11-11
CN110831668A (zh) 2020-02-21
IL271470A (en) 2020-01-30
AU2018287316A1 (en) 2020-02-06
IL271470B1 (en) 2025-03-01
CN110831668B (zh) 2024-04-12
MY203136A (en) 2024-06-10
WO2018234861A1 (en) 2018-12-27
EP3641888A1 (en) 2020-04-29
US11826404B2 (en) 2023-11-28
FI3641888T3 (fi) 2023-12-19
ES2965937T3 (es) 2024-04-17
US20210330761A1 (en) 2021-10-28
TWI868051B (zh) 2025-01-01
RU2020100080A (ru) 2021-07-23
BR112019027229A2 (pt) 2020-07-07
AU2018287316B2 (en) 2024-09-19
TW201904990A (zh) 2019-02-01
CA3068153A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
KR20200019217A (ko) Pai-1 과다발현과 관련된 병태의 플라스미노겐 치료
JP6783870B2 (ja) 心血管病を予防及び治療するための新しい方法
Wu et al. Inhibition of PAI-1: a new anti-thrombotic approach
JP5536198B2 (ja) 糖尿病性ケトアシドーシスを治療するための方法および組成物
Su et al. Prostaglandin E1 attenuates post-cardiac arrest myocardial dysfunction through inhibition of mitochondria-mediated cardiomyocyte apoptosis
CA3068637A1 (en) Gas mixtures containing low concentrations of xenon and argon provide neuroprotection without inhibiting the catalytic activity of thrombolytic agents
WO1997035609A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
Hsu et al. Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery
JP2002543148A (ja) カルボキシペプチダーゼｕ阻害剤とトロンビン阻害剤とを含有する医薬製剤
CN110511266B (zh) 一种小分子多肽及其用途
KR20180070708A (ko) 상처 치유를 위한 플라스미노겐 투여 요법
Martusevich et al. Ozone therapy in patients with burn disease
EP2560662A2 (en) Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
HK40029531B (en) Plasminogen treatment of conditions associated with pai-1 overexpression
HK40029531A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
Shiba et al. Arteriosclerotic changes after intravitreal injections of anti-vascular endothelial growth factor drugs in patients with exudative age-related macular degeneration
JP6289511B2 (ja) 羊水塞栓の治療剤
Cucinotta The inhibition of Prolyl Endopeptidase as a potential therapeutic target for the treatment of ischemic-reperfusion
WO2022224249A1 (en) Procoagulant peptides and use thereof
CN119661696A (zh) 一种多肽pm7及其在防治血栓中的应用
WO2024155293A1 (en) Method of inhibiting degrading protease activity in the skin
CN120026102A (zh) PGC-1α在制备治疗下肢静脉性溃疡复发药物中的应用
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
CN113301907A (zh) 用于治疗和/或改善伴有凝血障碍的败血症的药物
Ling et al. Research about the influence of alprostadil for the renal blood flow parameters and fibrosis indexes of patients with diabetic nephropathy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210618

Comment text: Request for Examination of Application

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241029

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D